Cohance Lifesciences Ltd
Cohance Lifesciences Q2 Results 2026 (FY27) investor presentation: Revenue & Margins
Q2 FY27 investor presentation: what the company reported on revenue, margins and capex.
- Revenue
- ₹477Cr
- Net profit
- ₹2Cr
- Margin
- 7.4%
Guidance rank: #43 of 87 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
Cohance Lifesciences Ltd Q2 FY27 key numbers
- Revenue
- Q2 FY27 revenue: INR 4,766 Mn, down 14.2% YoY.
As stated in Cohance Lifesciences Ltd's Q2 FY27 investor presentation · published 6 Nov 2026. Reported figures, not investment advice.
Based on Cohance Lifesciences Ltd's Q2 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Q2 FY27 revenue: INR 4,766 Mn, down 14.2% YoY (Page 8, 9). Q2FY27 Adjusted EBITDA: INR 459 Mn, margin 9.6%, down 64.4% YoY (from INR 1,288 Mn, 23.2% in Q2FY26).
From Cohance Lifesciences Ltd's Q2 FY27 earnings-call transcript · updated 6 Nov 2026.
How did Cohance Lifesciences' revenue grow in the September 2026 quarter?
- Q2 FY27 revenue: INR 4,766 Mn, down 14.2% YoY (Page 8, 9)
- Pharma CDMO revenue down 27.4% YoY in Q2 (Page 8)
- API+ segment revenue grew 6.2% YoY in Q2 (Page 8)
- Nucleic Acid business (Sapala) revenue grew 33.6% YoY in Q2 (Page 8, 26)
- Specialty Chemicals revenue declined 40.6% YoY in Q2 (Page 8)
- 1HFY27 revenue: INR 8,989 Mn, down 18.6% YoY (Page 12)
- H2 FY27 outlook: Revenue and EBITDA expected to grow YoY, with H2 stronger than H1, driven by Small Molecule deliveries, API+ resilience, and Sapala growth (Page 6)
2 more points from Cohance Lifesciences Ltd's call on revenue
Create a free account to keep reading this call
What happened to Cohance Lifesciences' margins in Q2 FY27?
See what Cohance Lifesciences Ltd said on profitability & margins — free account, 30 seconds.
What capex is Cohance Lifesciences planning?
- Capex spend:
- INR 2,154 Mn in FY26, INR 1,077 Mn in 1HFY27
- Capex as % of sales: 9.5% in FY26, 12% in 1HFY27
- Capacity expansion:
- Integration and capacity expansion ongoing across key growth platforms, supporting growth and maintaining liquidity as of 30 Sep 2026
2 more points from Cohance Lifesciences Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Is Cohance Lifesciences raising money or cutting debt?
See what Cohance Lifesciences Ltd said on fundraising & capital structure — free account, 30 seconds.
How big is Cohance Lifesciences' order book?
- The Pharma CDMO segment reports improved H2 visibility with a stronger Q3/Q4 order book and better commercial reload visibility expected to support sequential recovery in H2 FY27 (Page 24).
- Multiple reload orders have been received across existing commercial programmes, improving visibility into scheduled Q3/Q4 deliveries (Page 24).
- The API+ segment mentions a healthy order book supporting resilient year-on-year revenue growth despite challenges (Page 28).
2 more points from Cohance Lifesciences Ltd's call on order book
Create a free account to keep reading this call
Cohance Lifesciences Ltd — Quarterly revenue & net profit
Cohance Lifesciences Ltd Q2 FY27 results — key figures
| ₹ Cr | Q2 FY27 |
|---|---|
| Revenue | 477 |
| Operating profit (EBITDA) | 35 |
| Operating margin | 7.4% |
| Profit before tax | -11 |
| Net profit (PAT) | 2 |
| EPS (₹) | 0.40 |
Source: Cohance Lifesciences Ltd's results filing to NSE (consolidated), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹477 Cr, net profit ₹2 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Cohance Lifesciences Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Kilitch Drugs (Q2 FY27)
14.3%) . Key results statement takeaways from Kilitch Drugs (India) Ltd's Q2 FY27 results statement — and how it ranks against sector peers.
- NGL Fine Chem (Q2 FY27)
Consolidated: ₹15,870.73 lakhs . Key results statement takeaways from NGL Fine Chem Ltd's Q2 FY27 results statement — and how it ranks against sector peers.
- Mangalam Drugs (Q2 FY27)
59% growth. Key results statement takeaways from Mangalam Drugs and Organics Ltd's Q2 FY27 results statement — and how it ranks against sector peers.
- Astrazeneca Phar (Q2 FY27)
Year-on-year revenue growth for the quarter: Rs 7,291.0 million vs Rs 5,590.9 million, approximately 30.5% increase. Key results statement takeaways from Astraz
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Cohance Lifesciences Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Cohance Lifesciences Ltd Q2 FY27 results?
Q2 FY27 revenue: INR 4,766 Mn, down 14.2% YoY (Page 8, 9). Q2FY27 Adjusted EBITDA: INR 459 Mn, margin 9.6%, down 64.4% YoY (from INR 1,288 Mn, 23.2% in Q2FY26).
What is Cohance Lifesciences Ltd share price analysis?
Cohance Lifesciences Ltd currently shows a neutral. The stock trades at a P/E of 154.1 with a market cap of ₹16,589 Cr. Investors should review the full earnings analysis for detailed insights.
Is Cohance Lifesciences Ltd planning capital expenditure?
Capex spend:.
Keep Cohance Lifesciences Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.